General Information:

Id: 2,839 (click here to show other Interactions for entry)
Diseases: Cancer
Diabetes mellitus, type II - [OMIM]
Insulin resistance
Homo sapiens
article
Reference: Monami M et al.(2009) Sulphonylureas and cancer: a case-control study. Acta Diabetol 46: 279-284 [PMID: 19082520]

Interaction Information:

Comment After adjusting for concomitant therapies, exposure to metformin and gliclazide for more than 36 months was associated with a significant reduction in the risk of cancer. Conversely, use of glibenclamide for at least 36 months was associated with increased incidence of malignancies. Treatment with insulin, thiazolidinediones, or acarbose, was not associated with significant differences in the incidence of cancer. Long-term treatments with individual sulphonylureas could have differential effects on the risk of cancer. In particular, the possible protective effect of gliclazide, as well as the risk associated with glibenclamide, deserves further investigation.
Formal Description
Interaction-ID: 26185

drug/chemical compound

Thiazolidinedione

NOT affects_activity of

disease

Cancer

in diabetic patients